View of EVALUATION OF TREATMENT OUTCOMES AND ASSOCIATED FACTORS IN RECURRENT AND METASTATIC EPITHELIAL OVARIAN CANCER WITH CHEMOTHERAPY COMBINED WITH BEVACIZUMAB AT CAN THO ONCOLOGY HOSPITAL IN 2023 - 2025

Return to Article Details EVALUATION OF TREATMENT OUTCOMES AND ASSOCIATED FACTORS IN RECURRENT AND METASTATIC EPITHELIAL OVARIAN CANCER WITH CHEMOTHERAPY COMBINED WITH BEVACIZUMAB AT CAN THO ONCOLOGY HOSPITAL IN 2023 - 2025 Download Download PDF